VASCULAR BIOSCIENCES, INC.
Durham, NC · Biotech · Private
Inhalable liposomal formulation of fasudil and nitric oxide donor with cyclic peptide targeting for pulmonary arterial hypertension
- Grants
- $7.2M
- 7 awards
- Sector median: 1
- Raised
- —
- No Form D on record
- Contracts
- —
- No federal contracts on record
- Patents
- —
- No published records under this name
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓2017201820192020202120222023
| Date | Event | Source | Amount |
|---|---|---|---|
| Federal grant | Department of Health and Human Services · Phase II · HLS- Cyclic CAR peptide: a targeted therapy for pulmonary hypertension | $302,402 | |
| Federal grant | Department of Health and Human Services · Phase II · HLS- Cyclic CAR peptide: a targeted therapy for pulmonary hypertension | $1,255,432 | |
| Federal grant | Department of Health and Human Services · Phase II · HLS- Cyclic CAR peptide: a targeted therapy for pulmonary hypertension | $746,137 | |
| Federal grant | Department of Health and Human Services · Phase II · Inhaled Fasudil and DETA NONOate CAR-Targeted Liposomes for PAH | $330,004 | |
| Federal grant | Department of Health and Human Services · Phase II · Inhaled Fasudil and DETA NONOate CAR-Targeted Liposomes for PAH | $1,291,298 | |
| Federal grant | Department of Health and Human Services · Phase II · Inhaled Fasudil and DETA NONOate CAR-Targeted Liposomes for PAH | $2,298,168 | |
| Federal grant | Department of Health and Human Services · Phase II · Inhaled Fasudil and DETA NONOate CAR-Targeted Liposomes for PAH | $1,006,870 |
Federal grant · SBIR/STTR
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 2838 | ReAlta Life Sciences, Inc. | — | $94M |
| 2839 | Verve Therapeutics | — | $94M |
| 2840 | Scorpion Therapeutics | — | $297M |
| 2841 | VASCULAR BIOSCIENCES, INC. | — | — |
| 2842 | EXPRESSION THERAPEUTICS, LLC | — | — |
| 2843 | CinCor Pharma | — | $143M |
| 2844 | GRADIENT BIOMODELING, LLC | — | — |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.